Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you whenever you need it. Give us a call at 650-498-3333 or GuestServices@stanfordmed.org.
PHYSICIAN HELPLINE
Have a question? We're here to help!
Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
Gerlinde Wernig
Pathologist, Hematopathologist
Professional Overview
Professional Education
Residency: Stanford Hospital and Clinics (2013) CA
Fellowship: Stanford Hospital and Clinics (2012) CA
Residency: Stanford Hospital and Clinics (2011) CA
Fellowship: Friedrich-Wilhelms-University Bonn (2004) Germany
Medical Education: Medical University of Vienna (1999) Austria
Publications
STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2
Tam, W. F., Haehnel, P. S., Schueler, A., Lee, B. H., Okabe, R., & Kindler, T. (2013). STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2. CANCER RESEARCH, 73(1), 373-384.
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
Kim, D., Wang, J., Willingham, S. B., Martin, R., Wernig, G., & Weissman, I. L. (2012). Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. LEUKEMIA, 26(12), 2538-2545.
EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L
Wernig, G., Kharas, M. G., Mullally, A., Leeman, D. S., Okabe, R., & Gilliland, D. G. (2012). EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. LEUKEMIA, 26(4), 720-727.
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., & Ebert, B. L. (2010). Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. CANCER CELL, 17(6), 584-596.
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Loriaux, M. M., Levine, R. L., Tyner, J. W., Froehling, S., Scholl, C., & Druker, B. J. (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. BLOOD, 111(9), 4788-4796.
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Wernig, G., Gonneville, J. R. R., Crowley, B. J., Rodrigues, M. S., Reddy, M. M., & Sattler, M. (2008). The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. BLOOD, 111(7), 3751-3759.
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Werning, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., & Gilliland, D. G. (2008). Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. CANCER CELL, 13(4), 311-320.
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
Mercher, T., Wernig, G., Moore, S. A., Levine, R. L., Gu, T.-L., & Gilliland, D. G. (2006). JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. BLOOD, 108(8), 2770-2779.
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., & Levine, R. L. (2006). MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLOS MEDICINE, 3(7), 1140-1151.
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006). Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. BLOOD, 107(11), 4274-4281.
Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
Levine, R. L., & Wernig, G. (2006). Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 233-?.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
Lu, X. H., Levine, R., Tong, W., Wernig, G., Pikman, Y., & Lodish, H. (2005). Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102(52), 18962-18967.
The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment
Wernig, G., Janzen, V., SCHAFER, R., Zweyer, M., Knauf, U., & Wernig, A. (2005). The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102(33), 11852-11857.
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., & Gilliland, D. G. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. CANCER CELL, 7(4), 387-397.
Correction of CFTR malfunction and stimulation of Ca2+- activated Cl- channels restore HCO3- secretion in cystic fibrosis bile ductular cells
Zsembery, A., Jessner, W., Sitter, G., Spirli, C., Strazzabosco, M., & Graf, J. (2002). Correction of CFTR malfunction and stimulation of Ca2+- activated Cl- channels restore HCO3- secretion in cystic fibrosis bile ductular cells. HEPATOLOGY, 35(1), 95-104.